ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Network Pharmacology Integrated with Transcriptomics Analysis Reveals Ermiao Wan Alleviates Atopic Dermatitis via Suppressing MAPK and Activating the EGFR/AKT Signaling

Xia, Ting; Liang, Xiao; Liu, Chang-Shun; Hu, Yan-Nan; Luo, Zhen-Ye; Tan, Xiao-Mei*南方医科大学
Drug Design Development and Therapy2022DOI: 10.2147/DDDT.S384927
2被引4阅读
引用收藏
分享

摘要

Background: Ermiao Wan (EMW) is commonly used to treat atopic dermatitis (AD) in China. However, the pharmacological mechanisms underlying the action of EMW against AD remain unclear.Purpose: We aimed to determine the mechanisms underlying the effectiveness of EMW in the treatment of AD.Methods: We evaluated the effect of EMW on AD induced by dinitrochlorobenzene (DNCB) in BALB/C mice. To clarify the key components of EMW in AD treatment, the main components of EMW were identified using HPLC. Serum pharmacochemistry was used to analyze the absorbed ingredients from blood. Based on the phytochemical results, network pharmacology and molecular docking were used to predict the action of EMW. Skin transcriptomic analysis was used to validate the network pharmacology results. RT-qPCR,ELISA, and immunohistochemical were performed to validate the results of skin transcriptomics.Results: EMW improved the symptoms of AD, with less rashes, less spontaneous scratching, less inflammatory cell infiltration, and fewer allergic reactions. The established HPLC method is simple and reliable. Chlorogenic acid, phellodendrine, magnoflorine, jatrorrhizine, palmatine, berberine, and atractylodin were the key effective ingredients with a high blood concentration. Fifty-seven primary causal targets of EMW against AD were identified. These targets are mainly involved in ErbB signaling pathways including EGFR, AKT1, MAPK8, JUN, MAPK1. Molecular docking showed that EGFR, AKT1, MAPK8, JUN, MAPK1 had good binding force with EMW. In AD mice, EMW regulated the EGFR/AKT signaling through upregulation of Grb2, GAB1, Raf-1, EGFR, and AKT, and downregulation of MAPK1 and JUN, compared to that in the MD group.Conclusion: EMW could alleviate AD through activating EGFR/AKT signaling and suppressing MAPK. This study provides a theoretical basis for the clinical use of EMW.

学科与关键词

关键词
Ermiao Wanatopic dermatitisnetwork pharmacologyserum pharmacochemistryskin transcriptomeEGFRAKT signaling
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Drug Design Development and Therapy
发表日期
2022
卷期
第 16 卷
页码
4325-4341
DOI
10.2147/DDDT.S384927
语言
ENGLISH
期刊等级
3区
成果收录
SCIE
资助标注
National Key R&D Program of China; [2018YFC1704500]; [2018YFC1704503]

作者

  • X

    Xia, Ting (第一作者)

    southern med univ

  • L

    Liang, Xiao

    guilin med univ

查看全部 6 位作者收起作者
  • L

    Liu, Chang-Shun

    southern med univ

  • H

    Hu, Yan-Nan

    southern med univ

  • L

    Luo, Zhen-Ye

    southern med univ

  • T

    Tan, Xiao-Mei (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417